The rising demand for R&D in biopharmaceutical businesses is one of the key factors anticipated to propel the growth of the cell dissociation market during the forecast period. Additionally, it is projected that the favourable funding environment for cancer research and the rising incidence and prevalence of infectious and chronic diseases will fuel the expansion of the cell dissociation market. Furthermore, the rising attention on customised treatment and increase in the government funding for cell-based research is further expected to cushion the growth of the cell dissociation market. On the other hand, it is anticipated that the development of the cell dissociation market will be hampered further by the rising expense of cell-based research and the lack of infrastructure for cell-based research in the developing nations.
RECESSION IMPACT
The recession will have a significant effect on the market for cell dissociation solution. Even though it is anticipated that price inflation will decline in 2023, an increase in interest rates would undoubtedly cause the rate of economic growth to stall significantly. According to IMF predictions, global inflation will decline from 8.8% in 2022 to 6.5% in 2019. Only an 8.1% decline in inflation is anticipated in 2023, which would be less of a comfort to developing economies. Power and raw materials will be pricy for a while. Other factors that contribute to inflation include the partial reversal of globalisation, labour shortages in many Western countries that raise the cost of manufacturing, and the transition to a shared economy in response to the biggest threat to our species.
DRIVING FACTORS
Rising Demand for Cell-based Therapies to Drive Market Growth
Cell-based therapies use cells to repair or regenerate tissues or organs that have been injured or afflicted by disease. These treatments have drawn a lot of attention recently because they offer the potential to treat a variety of illnesses that are currently difficult or impossible to treat using conventional methods. Cell-based therapies are in rising demand because they have various advantages over conventional therapies, including less side effects, greater efficacy, and the potential to have long-lasting effects. Stem cell therapy, for instance, is being researched as a potential cure for ailments like heart disease, Parkinson's disease, and spinal cord injury. Similarly, CAR T-cell therapy has demonstrated promise in the treatment of specific cancers, such as leukaemia and lymphoma. Large numbers of certain cells are needed to create these medicines. In order to isolate and get these cells ready for usage in various therapies, cell dissociation solutions are crucial tools. As a result, the demand for cell dissociation treatments is growing along with the desire for cell-based therapies.
RESTRAINING FACTORS
High Cost Associated with Cell Dissociation Solution to Limit Market Growth
One of the biggest issues the market for cell dissociation solutions is high price. The high price of these goods is a result of a number of variables. First off, the ingredients required to make cell dissociation solutions can be pricey. Enzymes and other biological ingredients that are hard to get and expensive are used in many of these remedies. These materials could need to come from specialised vendors or go through intricate production procedures, which could raise the cost. Second, the process of creating cell dissociation solutions can be difficult and drawn out. Enzyme extraction, purification, and formulation are common processes in the production process. Each of these phases calls for specialised tools and knowledge, which raises the production cost.
SEGMENTATION
By Type
Based on type, the cell dissociation solution market is segmented into tissue dissociation and cell detachment. The tissue dissociation category dominated the market in 2022. To produce single-cell suspensions from tissue samples for use in cell culture, flow cytometry, and gene expression studies, a method known as tissue dissociation is performed. A popular enzyme-based solution for tissue dissociation is called cell dissociation solution. Proteolytic enzymes, including collagenase or trypsin, are frequently present in cell dissociation solutions because they have the ability to degrade the extracellular matrix (ECM) and separate cells from one another. To keep the pH of the solution stable and guard against cell damage, the solution also contains a variety of buffering agents.
By Product
Based on product, the cell dissociation solution market is segmented into enzymatic dissociation products (collagenase, trypsin, papain, elastase, dnase, hyaluronidase and other enzymes), non-enzymatic dissociation products and instruments. The market segment expected to experience the highest increase throughout the projection period is non-enzymatic dissociation products. Due to its benefits, including their ready-to-use nature, lack of toxicity, and increased yield of viable cells during the dissociation process, non-enzymatic dissociation products have seen an increase in demand.
By Tissue
Based on tissue, the cell dissociation solution market is segmented into connective tissues, epithelial tissues and other type tissues (skeletal and muscles tissues). The connective tissues category dominated the market in 2022. One of the tissues that can be separated using cell dissociation solutions is connective tissue. Connective tissue is a form of tissue that connects various tissues and organs together as well as giving the body structural support. Fibroblasts, adipocytes, immunological cells, as well as extracellular matrix (ECM) substances including collagen, elastin, and glycosaminoglycans, are among the several cell types that make up this structure. In order to isolate and culture particular cell types from connective tissue or to examine the ECM composition and characteristics of diverse connective tissues, it is crucial to dissociate connective tissue utilising cell dissociation solutions.
By End User
Based on end user, the cell dissociation solution market is segmented into pharmaceutical and biotechnology companies, research and academics and other end users. The pharmaceutical and biotechnology companies category dominated the market in 2022. Cell dissociation solutions are widely used in the pharmaceutical and biotechnology industries for diverse applications in research and development. These businesses frequently use cell dissociation solutions to isolate and cultivate cells for drug discovery, toxicity testing, and therapeutic development. Pharmaceutical businesses separate tissues and remove particular cell types for drug testing and screening using cell dissociation solutions. For instance, it is possible to separate cancer cells from tumour tissues using cell dissociation solutions, which can then be used to test potential anticancer medications. Furthermore, cells are isolated from animal tissues for pharmacokinetic research using cell dissociation solutions.
REGIONAL INSIGHTS
North America is projected to hold the largest share of the cell dissociation solution market over the forecast period due to the increase in the prevalence of chronic diseases like cancer. Furthermore, the emergence of significant key players and the rising industrial and academic interest in life sciences research and development would both support the growth of the cell dissociation market in the area throughout the course of the projected year. On the other hand, the Asia Pacific cell dissociation solution market is anticipated to be driven by an increase in biotech start-ups as a result of cost-effective cell dissociation reagent manufacture, a rise in the demand for these reagents, and an increase in cell maintenance banks and specialised research institutions. Furthermore, the market is growing as a result of increased demand from research institutes, rising research and development investments, and high adoption of innovative and technologically cutting-edge products.
LIST OF KEY COMPANIES PROFILED:
- BD
- Thermo Fisher Scientific Inc.
- F. Hoffmann-La Roche Ltd
- GE Healthcare
- Merck KgaA
- ATCC
- REPROCELL Inc.
- ALSTEM
- CellSystems
- BIOCOM AG
- Biological Industries USA, Inc.
- Pelobiotech
- BrainBits, LLC
- Labochema
- Himedia Laboratories
- BIOCOMPARE
- PAN-Biotech
- Gemini Bio-Products
- Miltenyi Biotec
- STEMCELL Technologies, Inc.
- Cyagen Biosciences, Inc.
- PromoCell GmbH
- Irvine Scientific
- Sigma-Aldrich Co. LLC
- Others
| Attributes | Details |
| Market Size in 2022 | USD 294.9 Million |
| Market Forecast in 2030 | USD 872.8 Million |
| Compound Annual Growth Rate | 14.90 % |
| Unit | Revenue (USD Million) and Volume (Kilo Tons) |
| Segmentation | By Type, By Product, By Tissue, By End Users and By Geography |
| By Type |
|
| By Product |
|
| By Tissue |
|
| By End User |
|
| By Region |
|
| Base Year | 2022 |
| Historical Year | 2016-2021 |
| Forecast Year | 2023-2030 |
